To validate our gene-expression analyses in a larger, independent cohort, we used publicly available gene-expression data of LAG-3 with associated tumor characteristics, as well as follow-up data [24], in an unselected cohort of breast cancer patients (n = 4929), and in the triple-negative breast cancer subgroup. This evidence concerns the gene LAG3 and triple-negative breast carcinoma.